Dr. Umar

This study investigated whether the gut microbiome harbors a distinct microbial signature associated with mild cognitive impairment (MCI) in individuals with Parkinson’s disease (PD). Prior research has established significant differences in the gut microbiome between PD patients and healthy controls, but the question of whether specific gut microbiome changes are linked to […]

This study identified a taurine-based microbiome-metabolism axis in Parkinson’s disease, showing that gut dysbiosis impairs taurine metabolism and exacerbates PD pathology. Restoring taurine levels or beneficial microbes alleviates disease features, highlighting potential microbiome-targeted interventions.

This multi-omics meta-analysis identifies depletion of Blautia as a robust microbiome signature linked to Parkinson’s disease across feces, blood, and brain, highlighting its potential diagnostic value and mechanistic ties to neurodegeneration via mitochondrial and inflammatory pathways.

This study revealed a PD-specific oral-gut microbiome axis, with increased oral Lactobacillus linked to gut dysbiosis and reduced glutamate/arginine biosynthesis. Shotgun metagenomics identified superior functional microbial signatures for PD, underscoring the importance of functional profiling in clinical microbiome research.

This study links increased Desulfovibrio and Parkinson’s disease severity, identifying a Desulfovibrio MAG with strong hydrogen sulfide–producing potential and suggesting Desulfovibrio as both a biomarker and mechanistic contributor to PD progression via gut–brain axis disruption.

Cross-sectional metagenomic profiling shows that the gut microbiome in Parkinson’s disease differs from age-matched controls via selective loss of butyrate-producing taxa, especially Butyricimonas synergistica, with links to non-motor symptoms, ageing-related Bifidobacterium decline, and sleep-associated Roseburia in older adults.

This study links specific gut microbiome dysbiosis signatures in Parkinson’s disease to reduced brain NMNAT2 expression and worsening neurobehavioral and oxidative stress outcomes, highlighting FMT and NMNAT2 restoration as promising therapeutic avenues.

This large, prospective study found that gut microbiome alterations—particularly loss of anti-inflammatory, SCFA-producing bacteria—precede Parkinson’s disease, offering promising early biomarkers and highlighting microbial pathways linked to PD pathogenesis.

FGF21 modulates gut microbiota in Parkinson’s disease, reversing motor and cognitive deficits in PD mice while restoring brain and colon metabolic homeostasis. Key microbial shifts include enrichment of Ruminococcaceae and Lachnospiraceae, highlighting the microbiota–gut–brain axis as a therapeutic target.

This study reveals gender-specific gut microbiota alterations in Parkinson’s disease, linking distinct microbial signatures to brain activity differences via the gut-brain axis. Findings suggest sex-dependent microbial influences on PD pathology, emphasizing the importance of personalized approaches to diagnosis and treatment.

Differences in gut microbiota between Parkinson’s disease patients and controls seem to depend on multiple-frequently unmeasured-confounders. Monozygotic twins offer a unique model for controlling several factors responsible for interpersonal variation in gut microbiota.

This study reveals that gut microbiome alterations, especially reduced Lachnospiraceae taxa, are evident in treatment-naive, de novo Parkinson’s disease patients, supporting early involvement of the microbiome in PD pathogenesis, but highlights limited reproducibility of taxonomic biomarkers across cohorts.

This large metagenomic study identified widespread gut microbiome dysbiosis in Parkinson’s disease, with specific microbial and functional signatures linked to inflammation, neurodegeneration, and disease progression, offering concrete targets for future clinical interventions and biomarker discovery.

This case-control study identified distinct gut microbiome signatures in Parkinson’s disease, including reduced diversity and increased abundance of key phyla (Proteobacteria, Verrucomicrobiota/Akkermansia) and metabolic pathways, with microbial profiles varying by disease subtype and duration—suggesting clinical relevance for microbiome-based biomarkers in PD.

Study of altered gut microbiota in Parkinson’s disease with motor complications shows decreased Blautia and increased Lactobacillus in patients with wearing-off, suggesting specific microbial signatures linked to advanced PD.

This study demonstrated that combining gut microbiome profiles and dietary carbohydrate intake significantly improves the prediction of Parkinson’s disease, identifying key microbial taxa alterations and their clinical associations, supporting integrated biomarker strategies for diagnosis and management.

This year-long study shows persistent loss of butyrate-producing gut bacteria in Parkinson’s disease, with microbiome differences stable over time and modestly enhanced prediction of progression when combined with dietary data. Device-assisted therapies had variable, non-sustained microbiome impacts.

This study characterizes gut microbiota and metabolome differences across Parkinson’s disease motor phenotypes, identifying specific microbial and metabolic signatures associated with tremor dominant versus non-tremor dominant forms, and highlighting their potential role in disease progression and symptom severity.

This study shows that Parkinson’s disease is associated with decreased gut SCFA production, increased intestinal inflammation, and altered microbiome composition, with significant links to disease onset and severity. Findings suggest microbiome-mediated mechanisms may be key to PD progression and represent targets for intervention.

This study identifies distinct gut microbiome and metabolic signatures in Parkinson’s disease, highlighting decreased microbial folate biosynthesis and increased homocysteine production as key features, with implications for disease progression and potential clinical interventions.

This prospective study demonstrates that fecal microbiota transplantation can correct gut dysbiosis and significantly improve both gastrointestinal and motor symptoms in Parkinson’s disease patients with constipation, supporting FMT’s role as a potential adjunctive therapy targeting the gut-brain axis.

Turkish case–control data show reduced Firmicutes/SCFA producers and increased Lactobacillus and Akkermansia in PD, with dysbiosis severity tracking disease duration and non-motor symptoms, supporting a mechanistic gut–brain link.

A multi-cohort metagenomic meta-analysis reveals robust, globally consistent metabolic and gene-level alterations in the gut microbiome of Parkinson’s disease patients, highlighting functional dysbiosis, oxidative stress responses, and disrupted microbial signaling as potential diagnostic and therapeutic targets.

Shotgun metagenomics of saliva and stool in early Parkinson’s disease reveals higher gut richness, disrupted microbial networks, and specific oral and gut microbiome signatures that classify PD, with saliva taxa and constipation-linked diversity closely tied to autonomic symptom burden.